[Immunisation: leaps into the future. Viral hepatitis].
作者信息
Bayas J M, Vilella A
机构信息
Servei de Medicina Preventiva. UASP-IDIBAPS. Hospital Clínic. Universitat de Barcelona. España.
出版信息
Aten Primaria. 2002 Nov 15;30(8):514-20. doi: 10.1016/s0212-6567(02)79090-2.
Abstract
摘要
相似文献
1
[Immunisation: leaps into the future. Viral hepatitis].[免疫接种：迈向未来。病毒性肝炎]
Aten Primaria. 2002 Nov 15;30(8):514-20. doi: 10.1016/s0212-6567(02)79090-2.
2
[Active and passive prevention of viral hepatitis].[病毒性肝炎的主动和被动预防]
Internist (Berl). 1991 May;32(5):249-55.
3
[Clinical studies of viral hepatitis--epidemiology, immunology and prevention].[病毒性肝炎的临床研究——流行病学、免疫学与预防]
Nihon Naika Gakkai Zasshi. 1986 Feb;75(2):173-6.
4
Recent advances in DNA vaccine of hepatitis virus.肝炎病毒DNA疫苗的最新进展
Hepatobiliary Pancreat Dis Int. 2002 May;1(2):228-31.
5
Viral hepatitis: epidemiology, treatment, prevention.病毒性肝炎：流行病学、治疗与预防
Ethiop Med J. 2008 Apr;46(2):193-200.
6
[Vaccines against viral hepatitis. Current research and prospects].
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna. 1981 Jan-Feb;33(1):13-6.
7
[Prevention of viral hepatitis].
Nihon Naika Gakkai Zasshi. 1990 Aug 10;79(8):1001-6.
8
Hepatitis vaccines.肝炎疫苗
Dig Dis. 1997 Jan-Apr;15(1-2):1-22. doi: 10.1159/000171585.
9
Viral hepatitis.病毒性肝炎
Am J Nurs. 1983 Apr;83(4):571-86.
10
Symposium on clinical aspects in hepatitis virus infection. 1. Hepatitis viruses update.肝炎病毒感染临床方面研讨会。1. 肝炎病毒最新情况。
Intern Med. 2001 Feb;40(2):173-5.
本文引用的文献
1
Perspectives: towards a peptide-based vaccine against hepatitis C virus.展望：迈向基于肽的丙型肝炎病毒疫苗
Mol Immunol. 2001 Dec;38(6):475-84. doi: 10.1016/s0161-5890(01)00083-9.
2
Reflections on Epstein-Barr virus: some recently resolved old uncertainties.关于爱泼斯坦-巴尔病毒的思考：一些近期解决的旧有不确定性问题。
J Infect. 2001 Aug;43(2):111-5. doi: 10.1053/jinf.2001.0898.
3
Expression, purification, immunological characterization and application of Escherichia coli-derived hepatitis C virus E2 proteins.源自大肠杆菌的丙型肝炎病毒E2蛋白的表达、纯化、免疫学特性及应用
Biotechnol Appl Biochem. 2001 Oct;34(2):109-19. doi: 10.1042/ba20010036.
4
Control of a community-wide outbreak of hepatitis A by mass vaccination with inactivated hepatitis A vaccine.通过大规模接种甲型肝炎灭活疫苗控制社区范围内的甲型肝炎疫情。
Eur J Clin Microbiol Infect Dis. 2001 Mar;20(3):185-7. doi: 10.1007/s100960100461.
5
[Molecular biology of hepatitis C virus: implications for the development of new therapies and prophylactic vaccine].[丙型肝炎病毒的分子生物学：对新疗法和预防性疫苗开发的影响]
Med Clin (Barc). 2001 Feb 10;116(5):191-7. doi: 10.1016/s0025-7753(01)71766-6.
6
Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group.疫苗接种与多发性硬化症复发风险。多发性硬化症研究组的疫苗研究
N Engl J Med. 2001 Feb 1;344(5):319-26. doi: 10.1056/NEJM200102013440501.
7
Iatrogenic exposure to mercury after hepatitis B vaccination in preterm infants.早产儿接种乙肝疫苗后医源性汞暴露。
J Pediatr. 2000 May;136(5):679-81. doi: 10.1067/mpd.2000.105133.
8
From the Centers for Disease Control and Prevention. Alternate two-dose hepatitis B vaccination schedule for adolescents aged 11-15 years.源自疾病控制与预防中心。11至15岁青少年的乙型肝炎疫苗替代两剂接种方案。
JAMA. 2000 Apr 26;283(16):2100. doi: 10.1001/jama.283.16.2100-jwr0426-4-1.
9
[Prevention of transmissible diseases. Work Group for Transmissible Diseases of the PAPPS].
Aten Primaria. 1999 Dec;24 Suppl 1:99-117.
10
Recommendations regarding the use of vaccines that contain thimerosal as a preservative.关于使用含硫柳汞作为防腐剂的疫苗的建议。
MMWR Morb Mortal Wkly Rep. 1999 Nov 5;48(43):996-8.
Zotero 插件